proxyvotesnow.com

Home › Companies › Arrowhead Pharmaceuticals, Inc. › 2025-2026

Arrowhead Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Arrowhead Pharmaceuticals, Inc.’s Form 8-K, filed 2026-03-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 15Reported items
  • 388Asset managers
  • 3,854Fund votes
  • 2026-03-19Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Arrowhead Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Arrowhead Pharmaceuticals, Inc.

These tallies are Arrowhead Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-03-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arrowhead Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-03-19
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Christopher Anzalon 100,146,3661,622,01177,607 --17,955,558 Majority: yes
Elect Director: Mauro Ferrar 99,784,8481,986,67874,458 --17,955,558 Majority: yes
Elect Director: Hongbo L 92,692,4288,971,012182,544 --17,955,558 Majority: yes
Elect Director: Adeoye Olukoto 100,808,855852,631184,498 --17,955,558 Majority: yes
Elect Director: Michael Perr 70,427,87931,342,81475,291 --17,955,558 Majority: yes
Elect Director: Victoria Vakiene 99,264,1912,506,05175,742 --17,955,558 Majority: yes
Elect Director: William Waddill 91,907,4669,861,644256,341 --17,955,558 Majority: yes

Source: Arrowhead Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-03-20 — read the filing on EDGAR.

How asset managers voted at the Arrowhead Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 388 asset managers that disclosed a Arrowhead Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Arrowhead Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

34% fund support · no official result

FOR 34%AGAINST 66%

The 371 asset managers below cast 34% of the shares they voted on this item FOR (36,218,805 for, 70,785,030 against).

FOR: 36,218,805 (33.8%)AGAINST: 70,785,030 (66.1%)ABSTAIN: 51,581 (0.0%)NOT VOTED: 757 (0.0%)SPLIT: 224 (0.0%)
Largest asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock736,48619,010,490 00Against
Vanguard6,769,4168,672,066 10Against
Fidelity2,840,00110,728,765 00Against
Avoro Capital Advisors LLC7,371,3010 00For
State Street5,709,23549,413 00For
GEODE CAPITAL MANAGEMENT, LLC3,271,0840 00For
FRED ALGER MANAGEMENT, LLC02,564,143 00Against
Charles Schwab02,547,964 00Against
Janus Henderson02,468,624 00Against
Invesco02,032,508 00Against
Siren, L.L.C.1,615,4760 00For
T. Rowe Price01,598,117 00Against
DEERFIELD MANAGEMENT COMPANY, L.P.1,591,5590 00For
Northern Trust1,178,10566,455 00For
PICTET ASSET MANAGEMENT SA01,189,439 00Against
DRIEHAUS CAPITAL MANAGEMENT LLC01,170,616 00Against
MELLON INVESTMENTS Corp0857,633 00Against
Voya0856,424 00Against
Fisher Asset Management, LLC0811,995 00Against
ALGER INSTITUTIONAL FUNDS0804,346 00Against
UBS0795,961 00Against
ALGER FUNDS0732,137 00Against
PRINCIPAL GLOBAL INVESTORS0716,457 00Against
Vestal Point Capital, LP0697,700 00Against
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP0595,400 00Against

Showing the 25 largest of 371 asset managers. See all 371 in the interactive database.

2. APPROVAL OF THE ARROWHEAD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2021 INCENTIVE PLAN.

COMPENSATION

99.8% fund support · no official result

FOR 99.8%

The 107 asset managers below cast 99.8% of the shares they voted on this item FOR (50,117,069 for, 57,988 against).

FOR: 50,117,069 (99.8%)AGAINST: 57,988 (0.1%)ABSTAIN: 27,721 (0.1%)
Largest asset managers voting on “APPROVAL OF THE ARROWHEAD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2021 INCENTIVE PLAN.” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6057 10For
Fidelity6,850,7530 00For
State Street3,210,622176 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For
Putnam126,4000 00For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

3. Election of Directors: Adeoye Olukotun

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 106 asset managers below cast 99.9% of the shares they voted on this item FOR (50,336,475 for, 10,960 against).

FOR: 50,336,475 (99.9%)AGAINST: 10,960 (0.0%)ABSTAIN: 25,221 (0.1%)
Largest asset managers voting on “Election of Directors: Adeoye Olukotun” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6103 10For
Fidelity6,850,7530 00For
State Street3,210,7980 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan172,3680 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

4. Election of Directors: Christopher Anzalone

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 100,146,366AGAINST: 1,622,011

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Christopher Anzalon”): 100,146,366 for, 1,622,011 against, per its Form 8-K filed 2026-03-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 137,391,000 outstanding shares: 73% for, 1% against (74% of the company cast a for/against vote).

The 106 asset managers below cast 99.9% of the shares they voted on this item FOR (50,336,391 for, 11,043 against).

FOR 99.9%
FOR: 50,336,391 (99.9%)AGAINST: 11,043 (0.0%)ABSTAIN: 25,220 (0.1%)
Largest asset managers voting on “Election of Directors: Christopher Anzalone” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6085 00For
Fidelity6,850,7530 00For
State Street3,210,71781 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan172,3680 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

5. Election of Directors: Mauro Ferrari

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 99,784,848AGAINST: 1,986,678

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mauro Ferrar”): 99,784,848 for, 1,986,678 against, per its Form 8-K filed 2026-03-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 137,391,000 outstanding shares: 73% for, 1% against (74% of the company cast a for/against vote).

The 106 asset managers below cast 99.9% of the shares they voted on this item FOR (50,298,877 for, 48,558 against).

FOR 99.8%
FOR: 50,298,877 (99.9%)AGAINST: 48,558 (0.1%)ABSTAIN: 25,220 (0.1%)
Largest asset managers voting on “Election of Directors: Mauro Ferrari” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6076 00For
Fidelity6,850,7530 00For
State Street3,210,622176 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan172,3680 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

6. Election of Directors: Michael S. Perry

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

59% fund support · no official result

FOR 58%AGAINST 41%

The 106 asset managers below cast 59% of the shares they voted on this item FOR (29,457,122 for, 20,890,313 against).

FOR: 29,457,122 (58.5%)AGAINST: 20,890,313 (41.5%)ABSTAIN: 25,220 (0.1%)
Largest asset managers voting on “Election of Directors: Michael S. Perry” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock263,85314,510,585 00Against
Vanguard14,302,57538 00For
Fidelity2,843,9194,006,834 00Against
State Street3,210,622176 00For
Charles Schwab01,191,957 00Against
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust438,13825,480 00For
Jackson National118,615280,477 00Against
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable114,090195,680 00Against
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC0218,394 00Against
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan0172,368 00Against
Lincoln Financial161,29810,350 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

7. Election of Directors: Victoria Vakiener

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 99,264,191AGAINST: 2,506,051

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Victoria Vakiene”): 99,264,191 for, 2,506,051 against, per its Form 8-K filed 2026-03-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 137,391,000 outstanding shares: 72% for, 2% against (74% of the company cast a for/against vote).

The 106 asset managers below cast 99.9% of the shares they voted on this item FOR (50,336,470 for, 10,965 against).

FOR 99.9%
FOR: 50,336,470 (99.9%)AGAINST: 10,965 (0.0%)ABSTAIN: 25,220 (0.1%)
Largest asset managers voting on “Election of Directors: Victoria Vakiener” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6058 00For
Fidelity6,850,7530 00For
State Street3,210,7980 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan172,3680 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

8. Election of Directors: William Waddill

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 91,907,466AGAINST: 9,861,644

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: William Waddill”): 91,907,466 for, 9,861,644 against, per its Form 8-K filed 2026-03-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 137,391,000 outstanding shares: 67% for, 7% against (74% of the company cast a for/against vote).

The 106 asset managers below cast 91% of the shares they voted on this item FOR (45,773,446 for, 4,573,989 against).

FOR 91%9%
FOR: 45,773,446 (90.9%)AGAINST: 4,573,989 (9.1%)ABSTAIN: 25,220 (0.1%)
Largest asset managers voting on “Election of Directors: William Waddill” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,290,44112,172 00For
Fidelity2,897,4103,953,343 00Against
State Street3,210,7980 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National118,615280,477 00Against
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan0172,368 00Against
Lincoln Financial161,29810,350 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

9. RATIFICATION OF THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBER 30, 2026.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 103 asset managers below cast 99.9% of the shares they voted on this item FOR (50,052,516 for, 1 against).

FOR: 50,052,516 (99.9%)AGAINST: 1 (0.0%)ABSTAIN: 25,220 (0.1%)
Largest asset managers voting on “RATIFICATION OF THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SE” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6121 00For
Fidelity6,850,7530 00For
State Street3,210,7980 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For
Putnam126,4000 00For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

10. Election of Directors: Hongbo Lu

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

91% fund support · no official result

FOR 91%9%

The 102 asset managers below cast 91% of the shares they voted on this item FOR (45,640,914 for, 4,379,099 against).

FOR: 45,640,914 (91.2%)AGAINST: 4,379,099 (8.8%)ABSTAIN: 25,220 (0.1%)
Largest asset managers voting on “Election of Directors: Hongbo Lu” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,281,1420 00For
Fidelity2,897,4103,953,343 00Against
State Street3,210,7980 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National118,615280,477 00Against
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
Lincoln Financial161,2980 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For
Putnam126,4000 00For

Showing the 25 largest of 102 asset managers. See all 102 in the interactive database.

11. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

1.0% fund support · no official result

AGAINST 99.0%

The 11 asset managers below cast 1.0% of the shares they voted on this item FOR (6,183 for, 657,275 against).

FOR: 6,183 (0.9%)AGAINST: 657,275 (99.1%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
NORDEA INVESTMENT MANAGEMENT AB0322,575 00Against
JPMorgan0172,368 00Against
Empower0102,713 00Against
Wilshire Advisors LLC021,017 00Against
Metzler Asset Management GmbH020,695 00Against
CLEARWATER INVESTMENT TRUST6,02613,811 00Against
Bellevue Group AG01,843 00Against
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma01,818 00Against
TD Waterhouse Canada Inc.0399 00Against
Uniplan Investment Counsel, Inc.1570 00For
Athena Investment Management036 00Against

12. ELECTION OF DIRECTOR: HONGBO LU

DIRECTOR ELECTIONS

44% fund support · no official result

FOR 44%AGAINST 56%

The 6 asset managers below cast 44% of the shares they voted on this item FOR (144,675 for, 182,747 against).

FOR: 144,675 (44.2%)AGAINST: 182,747 (55.8%)ABSTAIN: 1 (0.0%)
Largest asset managers voting on “ELECTION OF DIRECTOR: HONGBO LU” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
JPMorgan0172,368 00Against
Empower102,7130 00For
Vanguard21,44229 10For
CLEARWATER INVESTMENT TRUST19,8370 00For
Lincoln Financial010,350 00Against
Advisors' Inner Circle Fund III6830 00For

13. Amend Omnibus Stock Plan

COMPENSATION

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (294,918 for, 0 against).

FOR: 294,918 (100.0%)
Largest asset managers voting on “Amend Omnibus Stock Plan” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
JPMorgan172,3680 00For
Empower102,7130 00For
CLEARWATER INVESTMENT TRUST19,8370 00For

14. Ratify KPMG LLP as Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (294,918 for, 0 against).

FOR: 294,918 (100.0%)
Largest asset managers voting on “Ratify KPMG LLP as Auditors” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
JPMorgan172,3680 00For
Empower102,7130 00For
CLEARWATER INVESTMENT TRUST19,8370 00For

15. To conduct an advisory (non-binding) vote to approve executive compensation

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

— fund support · no official result

ABSTAIN 99%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ABSTAIN: 47,049 (98.8%)NOT VOTED: 576 (1.2%)
Largest asset managers voting on “To conduct an advisory (non-binding) vote to approve executive compensation” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
STEELHEAD PARTNERS LLC00 47,0490Abstain
National Philanthropic Trust00 00Not Voted
IPConcept (Luxemburg) S.A.00 00--

Largest Arrowhead Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of Arrowhead Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 137,391,000 shares outstanding at the time of that meeting.

Top Arrowhead Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 14.37%
2Vanguard 11.24%
3Fidelity 9.88%
4Avoro Capital Advisors LLC 5.37%
5State Street 4.19%
6GEODE CAPITAL MANAGEMENT, LLC 2.38%
7FRED ALGER MANAGEMENT, LLC 1.87%
8Charles Schwab 1.85%
9Janus Henderson 1.80%
10Invesco 1.48%

Reported Arrowhead Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Arrowhead Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
BlackRock 13.22% 13F
Vanguard Group 11.13% 13F
Entities affiliated with Avoro Capital Advisors LLC 10.18% DEF14A
Avoro Capital Advisors LLC 10.06% 13G
FMR (Fidelity) 5.29% 13F
State Street 4.73% 13F
Geode Capital 3.11% 13F
Christopher Anzalone 2.76% DEF14A
Invesco 2.39% 13F
Goldman Sachs 1.27% 13F

Percentages above are of 137,391,000 shares outstanding, as reported by Arrowhead Pharmaceuticals, Inc. on its Form 10-Q dated 2025-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arrowhead Pharmaceuticals, Inc.’s 10-Q dated 2025-12-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Arrowhead Pharmaceuticals, Inc.'s shareholder meeting held 2026-03-19, in the 2025-2026 proxy season, 388 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,854 separate fund positions. Their filings are grouped here into 15 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Arrowhead Pharmaceuticals, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION. — the reporting funds cast 34% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Arrowhead Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).